High dose intravenous oestrogen (Fosfestrol) in the treatment of symptomatic, metastatic, hormone-refractory carcinoma of the prostate

Isaac J.T., Schulz I.I., Coffey D.S., Development of androgen resistance in prostatic cancer, Prostate Cancer, Part A. Research: Endocrine Treatment and Histopathology, pp. 21-31, (1987)

Fossa S.D., Aaronson N.K., Newling D., Quality of life in and treatment of hormone resistant metastatic prostatic cancer, Eur. J. Cancer, 26, (1990)

George N.J.R., Natural history of localized prostatic carcinoma managed by conservative therapy alone, Lancet, 1, (1988)

Dearnaley D.P., Bayly R.J., A'Hern R.P., Gadd J., Zivanovic M.M., Lewington V.J., Palliation of bone metastasis in prostate cancer, hemibody irradiation or strontium-89, Clin. Oncol., 4, (1992)

Klijn J.G.M., Scientific background of hormonal treatment of prostatic cancer, EORTC Genitourinary Group Monograph 7. Prostate Cancer and Testicular Cancer, pp. 7-22, (1990)

Thompson T.C., Growth factors and oncogenes in prostate cancer, Cancer Cells, 2, (1990)

Ferro M.A., Heinemann D., Smith P.J.B., Symes M.O., The effect of stilboestrol and testosterone on the incorporation of 75-selenomethionine by prostatic carcinoma cells, Br. J. Urol., 62, 2, (1988)

Schulz P., Vetter I., Fittler F., Evaluation of cytotoxic activity of stilboestrol and its phosphorylated derivative towards prostatic carcinoma, non-prostatic neoplastic and non-transformed cells, Urol. Int., 43, 1 SUPPL., (1988)

Schneider M.R., Schonenberger H., Effects of diethylstilboestrol and its mono- and diphosphate on experimental mammary and prostatic tumors, Urol. Int., 43, 1 SUPPL., (1988)

Ferro M.A., Gillatt D., Symes M.D., Smith P.J.B., High-dose intravenous estrogen therapy in advanced prostatic carcinoma: Use of serum prostate-specific antigen to monitor response, Urology, 34, 3, (1989)

Isaac J.T., Schulz I.I., Coffey D.S., Development of androgen resistance in prostatic cancer, Prostate Cancer, Part A. Research: Endocrine Treatment and Histopathology, pp. 21-31, (1987)

Fossa S.D., Aaronson N.K., Newling D., Quality of life in and treatment of hormone resistant metastatic prostatic cancer, Eur. J. Cancer, 26, (1990)

George N.J.R., Natural history of localized prostatic carcinoma managed by conservative therapy alone, Lancet, 1, (1988)

Dearnaley D.P., Bayly R.J., A'Hern R.P., Gadd J., Zivanovic M.M., Lewington V.J., Palliation of bone metastasis in prostate cancer, hemibody irradiation or strontium-89, Clin. Oncol., 4, (1992)

Klijn J.G.M., Scientific background of hormonal treatment of prostatic cancer, EORTC Genitourinary Group Monograph 7. Prostate Cancer and Testicular Cancer, pp. 7-22, (1990)

Thompson T.C., Growth factors and oncogenes in prostate cancer, Cancer Cells, 2, (1990)

Ferro M.A., Heinemann D., Smith P.J.B., Symes M.O., The effect of stilboestrol and testosterone on the incorporation of 75-selenomethionine by prostatic carcinoma cells, Br. J. Urol., 62, 2, (1988)

Schulz P., Vetter I., Fittler F., Evaluation of cytotoxic activity of stilboestrol and its phosphorylated derivative towards prostatic carcinoma, non-prostatic neoplastic and non-transformed cells, Urol. Int., 43, 1 SUPPL., (1988)

Schneider M.R., Schonenberger H., Effects of diethylstilboestrol and its mono- and diphosphate on experimental mammary and prostatic tumors, Urol. Int., 43, 1 SUPPL., (1988)

Ferro M.A., Gillatt D., Symes M.D., Smith P.J.B., High-dose intravenous estrogen therapy in advanced prostatic carcinoma: Use of serum prostate-specific antigen to monitor response, Urology, 34, 3, (1989)